Recombinant Human VEGF 206 (aa 27-232) Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10490-VE

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10490-VE-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

P15692.2

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all VEGF Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human VEGF protein
Ala27-Arg232

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala27

Predicted Molecular Mass

24 kDa

SDS-PAGE

26-30 kDa, under reducing conditions.

Activity

Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells.
The ED50 for this effect is 20-160 ng/mL.

Scientific Data Images for Recombinant Human VEGF 206 (aa 27-232) Protein, CF

Recombinant Human VEGF 206 (aa 27-232) Protein Bioactivity

Recombinant Human VEGF 206 (aa 27-232) Protein Bioactivity.

Recombinant Human VEGF 206 (aa 27-232) Protein (10490-VE) stimulates proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 20-120 ng/mL.

Recombinant Human VEGF 206 (aa 27-232) Protein SDS-PAGE.

2 μg/lane of Recombinant Human VEGF 206 (aa 27-232) Protein (Catalog # 10490-VE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 26-30 kDa and 38-44 kDa, respectively.

Formulation, Preparation and Storage

10490-VE
Formulation Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF

VEGF 206 (Vascular Endothelial Growth Factor-A or VEGF-A) is a 48-kDa covalently linked homodimeric protein member of the PDGF/VEGF family of molecules (1, 2). They are characterized by the presence of eight conserved cysteine residues and a cystine knot structure (3). Also known as vascular permeability factor (VPF), VEGF is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (4). VEGF-A mRNA undergoes alternative splicing events that generate several different isoforms, e.g. VEGF 121, VEGF 145, VEGF 165, VEGF 189, and VEGF 206 in humans (5). Whereas VEGF 188/189, 164/165, and 120/121 (rat/human, respectively) are the predominant forms expressed in most tissues and cells examined, VEGF 144/145 and 205/206 are rare variants. VEGF 144/145 is detected only in placenta, uterine tissues and endometrial carcinoma cell lines while VEGF 205/206 is detected only in fetal liver, placenta and adult lung (6).VEGF 206, the longest of all isoforms in human, along with VEGF 189 are highly basic proteins that bind to heparan sulfate both on the cell surface and in the extracellular matrix (ECM) where they retains bioactivity (7). VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (8, 9). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (10). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 11).

References

  1. Woolard, J. et al. (2009) Microcirculation 16:572.
  2. Ferrara, N. et al. (2003) Nat. Med. 9:669.
  3. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  4. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
  5. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  6. Burchardt T. et al. (1999) IUBMB Life. 48:405.
  7. Ferrara N. (2010) Mol Biol Cell. 21:687.
  8. Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
  9. Thurston, G. (2002) J. Anat. 200:575.
  10. Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
  11. Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.

Long Name

Vascular Endothelial Growth Factor

Alternate Names

MVCD1, VAS, Vasculotropin, VEGF-A, VEGFA, VPF

Entrez Gene IDs

7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)

Gene Symbol

VEGFA

UniProt

P15692.2

Additional VEGF Products

Product Documents for Recombinant Human VEGF 206 (aa 27-232) Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human VEGF 206 (aa 27-232) Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.